Results 31 to 40 of about 15,072 (244)

Vascular dysfunction and fibrosis in stroke-prone spontaneously hypertensive rats: the aldosterone-mineralocorticoid receptor-Nox1 Axis [PDF]

, 2017
Aims: We questioned whether aldosterone and oxidative stress play a role in vascular damage in severe hypertension and investigated the role of Nox1 in this process.
Ceravolo, Graziela, Graham, Delyth, Harvey, Adam P., Hood, Katie Y., Lopes, Rheure A., Montezano, Augusto C., Rios, Francisco, Touyz, Rhian M.   +7 more
core   +1 more source

Eplerenone Implantation Improved Adipose Dysfunction Averting RAAS Activation and Cell Division

Frontiers in Endocrinology, 2020
Introduction: Mineralocorticoid receptor (MR) activation within adipose tissue, triggers inflammation and metabolic syndrome development. The pharmacological blockade of MR provides beneficial effects for adipose tissue. Our study evaluates the impact of
Andrea Vecchiola, Andrea Vecchiola, Cristóbal A. Fuentes, Isidora Solar, Carlos F. Lagos, Maria Cecilia Opazo, Maria Cecilia Opazo, Natalia Muñoz-Durango, Natalia Muñoz-Durango, Claudia A. Riedel, Claudia A. Riedel, Gareth I. Owen, Gareth I. Owen, Alexis M. Kalergis, Alexis M. Kalergis, Alexis M. Kalergis, Carlos E. Fardella, Carlos E. Fardella, Carlos E. Fardella   +18 more
doaj   +1 more source

The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury

Frontiers in Pharmacology, 2021
The therapeutic indices (TIs) and efficacy of the non-steroidal mineralocorticoid receptor antagonist (MRA) KBP-5074 and steroidal MRA eplerenone were evaluated in a uninephrectomized Sprague Dawley rat model of aldosterone-mediated renal disease. In two
Frédéric Jaisser, Xiaojuan Tan, Shuangshuang Chi, Jinrong Liu, Ping Wang, Mark Bush, Vincent Benn, Y. Fred Yang, Jay Zhang   +8 more
doaj   +1 more source

Aldosterone upregulates transient receptor potential melastatin 7 (TRPM7) [PDF]

, 2016
Transient receptor potential melastatin 7 (TRPM7) is a ubiquitously expressed Mg2+-permeable ion channel fused to a C-terminal α-kinase domain. Recently, aldosterone was shown to increase intracellular Mg2+ levels and alter inflammatory signaling in ...
Jolly, Anna, Miquel, Perrine, Shrier, Alvin, Touyz, Rhian M., Valinsky, William C.   +4 more
core   +1 more source

Eplerenone for hypertension [PDF]

Cochrane Database of Systematic Reviews, 2011
Eplerenone is an aldosterone receptor blocker that is chemically derived from spironolactone. In Canada, it is indicated for use as adjunctive therapy to reduce mortality for heart failure patients with New York Heart Association (NYHA) class II systolic chronic heart failure and left ventricular systolic dysfunction.
Tina Sc, Tam, May Hy, Wu, Sarah C, Masson, Matthew P, Tsang, Sarah N, Stabler, Angus, Kinkade, Anthony, Tung, Aaron M, Tejani   +7 more
openaire   +2 more sources

PF-03882845, a non-steroidal mineralocorticoid receptor antagonist, prevents renal injury with reduced risk of hyperkalemia in an animal model of nephropathy

Frontiers in Pharmacology, 2013
The mineralocorticoid receptor (MR) antagonists PF 03882845 and eplerenone were evaluated for renal protection against aldosterone mediated renal disease in uninephrectomized Sprague Dawley (SD) rats maintained on a high salt diet and receiving ...
Stephen eOrena, Stephen eOrena, Tristan eMaurer, Rena eEudy, Rena eEudy, Li eShe, Darla eDash, Paula eLoria, Mary Ellen eBanker, Vincent eBernardo, Meera eTugnait, Carlin eOkerberg, Jessie eQian, Carine M Boustany-Kari, Carine M Boustany-Kari   +14 more
doaj   +1 more source

Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme [PDF]

, 2016
Aims We investigated the association between worsening renal function (WRF) that occurs during renin–angiotensin–aldosterone system inhibition initation and outcome in heart failure (HF) patients with preserved ejection fraction (HFPEF) and compared ...
Brenner, Clark, Damman, Damman, Damman, Hillege, Lesogor, Lewis, Lindenfeld, Massie, McAlister, McMurray, National Institute for Health and Clinical Excellence, Pfeffer, Rossignol, Rossignol, Rusinaru, Swedberg, Testani, Vardeny, Yancy, Yusuf   +21 more
core   +1 more source

Eplerenone in the Treatment of Polypoidal Choroidal Vasculopathy

Case Reports in Ophthalmology, 2015
Overactivation of mineralocorticoid receptor pathways has been implicated in the pathophysiology of central serous chorioretinopathy (CSCR). Recently, mineralocorticoid receptor antagonists such as eplerenone have demonstrated success in treating ...
Kapil G. Kapoor, Alan L. Wagner
doaj   +1 more source

Hepatoprotective effect of the selective mineralocorticoid receptor antagonist, eplerenone against carbon tetrachloride-induced liver injury in rats

Annals of Hepatology, 2012
Background. Eplerenone is a selective mineralocorticoid receptor (MR) antagonist, and its potential protective role in cardiovascular injury has been reported by several studies. However, whether and how this drug can ameliorate hepatic injury in rats is
Ashraf Taye, Ihab T. Abdel-Raheem
doaj   +1 more source

Eplerenone versus placebo for chronic central serous chorioretinopathy: the VICI RCT

Efficacy and Mechanism Evaluation, 2021
Background: In chronic central serous chorioretinopathy, fluid accumulates in the subretinal space and causes permanent vision loss in ≈ 30% of patients. There is no definitive treatment.
Andrew Lotery, Sobha Sivaprasad, Abby O’Connell, Rosie A Harris, Lucy Culliford, Angela Cree, Savita Madhusudhan, Helen Griffiths, Lucy Ellis, Usha Chakravarthy, Tunde Peto, Chris A Rogers, Barnaby C Reeves   +12 more
doaj   +1 more source